Pathology of Prostate Cancer

[1]  D. Lin,et al.  Role of radical prostatectomy in metastatic prostate cancer: A review. , 2017, Urologic oncology.

[2]  C. Bach,et al.  Radical prostatectomy for locally advanced and metastatic prostate cancer , 2017, Annals of the Royal College of Surgeons of England.

[3]  Jennifer R. Rider,et al.  Perineural Invasion and Risk of Lethal Prostate Cancer , 2017, Cancer Epidemiology, Biomarkers & Prevention.

[4]  Ronald C. Chen,et al.  Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  H. Salehiniya,et al.  Incidence and mortality of prostate cancer and their relationship with the Human Development Index worldwide , 2016, Prostate international.

[6]  M. Divatia,et al.  Intraductal Carcinoma of the Prostate Gland: Recent Advances , 2016, Yonsei medical journal.

[7]  L. True,et al.  A Novel System for Estimating Residual Disease and Pathologic Response to Neoadjuvant Treatment of Prostate Cancer , 2016, The Prostate.

[8]  L. Egevad,et al.  A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score. , 2016, European urology.

[9]  B. Delahunt,et al.  The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System , 2015, The American journal of surgical pathology.

[10]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[11]  J. Epstein,et al.  Sarcomatoid Carcinoma of the Prostate: Retrospective Review of a Case Series From the Johns Hopkins Hospital. , 2015, Urology.

[12]  J. Epstein,et al.  A subset of prostatic basal cell carcinomas harbor the MYB rearrangement of adenoid cystic carcinoma. , 2015, Human pathology.

[13]  A. Evans,et al.  Active surveillance for the management of localized prostate cancer: Guideline recommendations. , 2015, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[14]  Ewout W Steyerberg,et al.  Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer , 2015, Modern Pathology.

[15]  B. Sarbay,et al.  The association of the cribriform pattern with outcome for prostatic adenocarcinomas. , 2014, Pathology, research and practice.

[16]  B. Delahunt,et al.  Best Practices Recommendations in the Application of Immunohistochemistry in Urologic Pathology: Report From the International Society of Urological Pathology Consensus Conference , 2014, The American journal of surgical pathology.

[17]  A. Chinnaiyan,et al.  HOXB13 G84E–related Familial Prostate Cancers: A Clinical, Histologic, and Molecular Survey , 2014, The American journal of surgical pathology.

[18]  B. Miles,et al.  De novo large cell neuroendocrine carcinoma of the prostate gland with pelvic lymph node metastasis: a case report with review of literature. , 2014, International Journal of Clinical and Experimental Pathology.

[19]  B. Miles,et al.  Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions. , 2014, International journal of clinical and experimental pathology.

[20]  C. Magi-Galluzzi,et al.  Incidence and clinicopathological characteristics of intraductal carcinoma detected in prostate biopsies: a prospective cohort study , 2013, Histopathology.

[21]  Moratalla Charcos Lm,et al.  CARCINOMA NEUROENDOCRINO DE CÉLULA GRANDE PROSTÁTICO. A PROPÓSITO DE UN CASO , 2013 .

[22]  Alan W Partin,et al.  Prognostic Gleason grade grouping: data based on the modified Gleason scoring system , 2013, BJU international.

[23]  L. Egevad,et al.  Histopathological features of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy specimens , 2013, Virchows Archiv.

[24]  P. Humphrey,et al.  Foamy gland adenocarcinoma of the prostate: incidence, Gleason grade, and early clinical outcome. , 2012, Human pathology.

[25]  Bruce J Trock,et al.  Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. , 2012, European urology.

[26]  A. Osunkoya,et al.  A comprehensive review of incidence and survival in patients with rare histological variants of prostate cancer in the United States from 1973 to 2008 , 2012, Prostate Cancer and Prostatic Diseases.

[27]  P. Humphrey.  Histological variants of prostatic carcinoma and their significance , 2012, Histopathology.

[28]  B. Delahunt,et al.  Therapy‐associated effects in the prostate gland , 2012, Histopathology.

[29]  B. Delahunt,et al.  International Society of Urological Pathology (ISUP) Consensus Conference on Handling and Staging of Radical Prostatectomy Specimens. Working group 4: seminal vesicles and lymph nodes , 2011, Modern Pathology.

[30]  M. Humphreys,et al.  Primary signet ring cell carcinoma of the prostate. , 2010, Mayo Clinic proceedings.

[31]  J. Epstein,et al.  Intraductal carcinoma of the prostate without invasive carcinoma on needle biopsy: emphasis on radical prostatectomy findings. , 2010, Journal of Urology.

[32]  K. Do,et al.  Morphologic characterization of preoperatively treated prostate cancer: toward a post-therapy histologic classification. , 2010, European urology.

[33]  P. Humphrey,et al.  Microcystic Adenocarcinoma of the Prostate: A Variant of Pseudohyperplastic and Atrophic Patterns , 2010, The American journal of surgical pathology.

[34]  L. True,et al.  Histologic changes associated with neoadjuvant chemotherapy are predictive of nodal metastases in patients with high-risk prostate cancer. , 2010, American journal of clinical pathology.

[35]  J. Epstein,et al.  A pathological reassessment of organ-confined, Gleason score 6 prostatic adenocarcinomas that progress after radical prostatectomy. , 2009, Human pathology.

[36]  A. Renshaw,et al.  Protocol for the examination of specimens from patients with carcinoma of the prostate gland. , 2009, Archives of pathology & laboratory medicine.

[37]  G. Lockwood,et al.  Twenty‐four‐month postradiation prostate biopsies are strongly predictive of 7‐year disease‐free survival , 2009, Cancer.

[38]  J. Epstein,et al.  Prognosis of Mucinous Adenocarcinoma of the Prostate Treated by Radical Prostatectomy: A Study of 47 Cases , 2008, The American journal of surgical pathology.

[39]  M. Terris,et al.  Risk stratification of men with Gleason score 7 to 10 tumors by primary and secondary Gleason score: results from the SEARCH database. , 2007, Urology.

[40]  G. Chebil,et al.  Urothelial carcinoma in the prostatic urethra and prostate: current controversies , 2007, Expert review of anticancer therapy.

[41]  R. Montironi,et al.  α-methylacyl-CoA racemase (P504S)/34βE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy , 2007 .

[42]  A. Parwani,et al.  Pleomorphic Giant Cell Adenocarcinoma of the Prostate: Report of 6 Cases , 2006, The American journal of surgical pathology.

[43]  A. Evans,et al.  Large Cell Neuroendocrine Carcinoma of Prostate: A Clinicopathologic Summary of 7 Cases of a Rare Manifestation of Advanced Prostate Cancer , 2006, The American journal of surgical pathology.

[44]  L. Truong,et al.  Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. , 2006, Human pathology.

[45]  R. Shah,et al.  Clonality of sarcomatous and carcinomatous elements in sarcomatoid carcinoma of the prostate. , 2006, Urology.

[46]  G. Bartsch,et al.  The effect of percentage free prostate‐specific antigen (PSA) level on the prostate cancer detection rate in a screening population with low PSA levels , 2005, BJU international.

[47]  D. Bostwick,et al.  Pleomorphic giant cell carcinoma of the prostate. , 2005, Archives of pathology & laboratory medicine.

[48]  Ximing J. Yang,et al.  Altered expression of alpha-methylacyl-coenzyme A racemase in prostatic adenocarcinoma following hormone therapy. , 2005, American journal of clinical pathology.

[49]  T. Tsuzuki,et al.  Prediction of extraprostatic extension in the neurovascular bundle based on prostate needle biopsy pathology, serum prostate specific antigen and digital rectal examination. , 2005, The Journal of urology.

[50]  J. Epstein,et al.  Utility of immunohistochemistry for alpha-methylacyl-CoA racemase in distinguishing atrophic prostate cancer from benign atrophy. , 2004, Human pathology.

[51]  J. Epstein,et al.  Expression and Diagnostic Utility of Alpha-Methylacyl-CoA-Racemase (P504S) in Foamy Gland and Pseudohyperplastic Prostate Cancer , 2003, The American journal of surgical pathology.

[52]  P. Humphrey,et al.  Multiple Measures of Carcinoma Extent Versus Perineural Invasion in Prostate Needle Biopsy Tissue in Prediction of Pathologic Stage in a Screening Population , 2003, The American journal of surgical pathology.

[53]  M. Rubin,et al.  Basal Cell Cocktail (34&bgr;E12 + p63) Improves the Detection of Prostate Basal Cells , 2003, The American journal of surgical pathology.

[54]  A W Partin,et al.  Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. , 2000, Urology.

[55]  Ximing J. Yang,et al.  Distinction of basaloid carcinoma of the prostate from benign basal cell lesions by using immunohistochemistry for bcl-2 and Ki-67. , 1998, Human pathology.

[56]  A. Renshaw,et al.  Biochemical Outcome after radical prostatectomy, external beam Radiation Therapy, or interstitial Radiation therapy for clinically localized prostate cancer , 1998 .

[57]  P. Humphrey,et al.  Prostatic adenocarcinoma with atrophic features: a study of 202 consecutive completely embedded radical prostatectomy specimens. , 1998, American journal of clinical pathology.

[58]  D. Bostwick,et al.  The pathology of early prostate cancer , 1989, CA: a cancer journal for clinicians.

[59]  Rohrschneider Lr.  Incidental adenocarcinoma in transurethral resections of the prostate. Partial versus complete microscopic examination. , 1987 .

[60]  W. Murphy,et al.  Incidental Carcinoma of the Prostate How Much Sampling is Adequate? , 1986, The American journal of surgical pathology.

[61]  J. Kovi,et al.  Ductal spread in prostatic carcinoma , 1985, Cancer.

[62]  V. Dube,et al.  Papillary primary duct adenocarcinoma of the prostate. , 1972, The Journal of urology.

[63]  N. Ende,et al.  CARCINOMA ORIGINATING IN DUCTS SURROUNDING THE PROSTATIC URETHRA. , 1960, American journal of clinical pathology.